Iqvia rolling out clinically-focused tech solutions, taking patient-centric focus to ‘the next level’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags: IQVIA, Clinical trials, Technology, SaaS, Artificial intelligence

Iqvia is expanding its alliance with Salesforce through which the companies will release SaaS and technology-enabled services to automate clinical trial processes and reduce patient burden.

Salesforce is a global customer relationship management (CRM) and Software as a Service (SaaS) solutions provider.

According to Iqiva, the clinical suite will include products to automate study processes and augment research and development insights from artificial intelligence (AI) and machine learning. It also will include services to support patient, clinician connections.

The multi-year alliance – terms of which have not been disclosed – was first announced in April 2017​.

“Through this expansion of our partnership with Salesforce, we are using its best-in-class platforms and Salesforce Health Cloud, a cloud-based application, to build our growing one-of-a-kind technology suite to help drive health care forward for patients,”​ Tal Rosenberg, senior vice president, Global Technology Solutions at Iqvia​ told us.

Rosenberg said the modular solutions will help the company reduce the length, cost, and patient burden from clinical trials through commercialization. “Also, this suite allows us to take our patient-centric focus to the next level to best meet the needs of our clients,”​ he added.

The partnership structure allows Iqvia to roll out multiple products and capabilities. As part of this, the company launched a new suite of virtual study options earlier this year​ and will continue to release products in the first half of 2019.

Making smarter decisions with technology

The expanded partnership with Salesforce falls under the Iqvia Technologies strategy and brand, which Rosenberg said helps the company brainstorm, develop, and offer technology solutions for the industry “to make smarter decisions across the entire product lifecycle.”

“Technology is truly helping us reimagine solutions in ways we’ve never done before,”​ he added.

However, Rosenberg explained that enterprise technology can be difficult to use and an inhibitor of change, noting that it is not fit for purpose and is plagued with integration challenges.

“Connecting different data sources at varying phases of a product’s lifecycle can be difficult and inefficient—wasting time and money that the industry can’t afford to do,” ​he said.

Iqvia aims to bring intelligence into the “points of decisions” ​through artificial intelligence and machine learning capabilities “and not just relying on data entry points through non-connected solutions,”​ said Rosenberg.

He added, “As part of our overall efforts to bring in the customer experience as much as possible, intuitive design with the end user in mind is key.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more